Journal article
Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial
Abstract
AIMS: Cardiovascular (CV) disease is a major cause of reduced life expectancy in type 1 diabetes (T1D). Intensive insulin therapy prevents CV complications but is constrained by hypoglycaemia and weight gain. Adjunct metformin reduces insulin dose requirement and stabilizes weight but there are no data on its cardiovascular effects. We have therefore initiated an international double-blind, randomized, placebo-controlled trial (REMOVAL: …
Authors
Petrie JR; Chaturvedi N; Ford I; Hramiak I; Hughes AD; Jenkins AJ; Klein BE; Klein R; Ooi TC; Rossing P
Journal
Diabetes Obesity and Metabolism, Vol. 19, No. 4, pp. 509–516
Publisher
Wiley
Publication Date
April 2017
DOI
10.1111/dom.12840
ISSN
1462-8902
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdultAtherosclerosisBlood GlucoseBody WeightCarotid Intima-Media ThicknessCholesterol, LDLClinical ProtocolsDiabetes Mellitus, Type 1Disease ProgressionDouble-Blind MethodDrug Therapy, CombinationFemaleGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulinMaleMetforminMiddle AgedRisk FactorsSingle-Blind Method